Vol 6 n° 3
- Parkinson's disease
Past issues
Contributors
How to publish
Contributions and comments
Home
Alert
To print this page in good conditions, please select the "Landscape" mode of your printer.
|
Select and print
|
2 8 1
B a s i c r e s e a r c h
Copyright © 2004 LLS SAS. All rights reserved
www.dialogues-cns.org
Postmortem studies in Parkinsons disease
Andreas Hartmann, MD
No animal model to date perfectly replicates Parkinsons
disease (PD) etiopathogenesis, and the anatomical orga-
nization of the nigrostriatal system differs considerably
between species. Human postmortem material therefore
remains the gold standard for both formulating
hypotheses for subsequent testing in in vitro and in vivo
PD models and verifying hypotheses derived from exper-
imental PD models with regard to their validity in the
human disease. This article focuses on recent and rele-
vant fields in which human postmortem work has gen-
erated significant impact in our understanding of PD.
These fields include Lewy body formation, regional vul-
nerability of dopaminergic neurons, oxidative/nitrative
cellular stress, inflammation, apoptosis, infectious and
environmental agents, and nondopaminergic lesions.
© 2004, LLS SAS
Dialogues Clin Neurosci
. 2004;6:281-293.
Keywords:
Parkinsons disease; pathogenesis; etiology; postmortem study;
Lewy body formation; dopaminergic neuron; cellular stress
Author affiliations:
Fédération de Neurologie, Hôpital de la Salpêtrière, Paris,
France
Address for correspondence:
Andreas Hartmann, MD, Centre
dInvestigation Clinique, Hôpital de la Salpêtrière, 47, Boulevard de lHôpital,
75013 Paris, France
(e-mail: hartmann@ccr.jussieu.fr)
he history of human postmortem studies in
Parkinsons disease (PD) begins at the end of the 1950s
with two seminal papers: Carlssons original suggestion
that dopamine (DA) may be a transmitter in the central
nervous system (CNS) and be involved in the control of
motor function, and thus in the parkinsonian syndrome
1
;
and the article by Ehringer and Hornykiewicz,
2
which
proved the significant reduction in DA concentration in
the neostriatum of patients suffering from sporadic PD.
In 1973, these initial observations were followed by
demonstration of a correlation between DA cell loss in
the substantia nigra pars compacta (SNpc,
Figure 1
) and
striatal DA concentrations in PD.
3
Interestingly, this study
suggested that the classical parkinsonian symptom triad
of PD appears when striatal DA concentrations are low-
ered by approximately 80%; however, this decline corre-
sponds to only 50% of SNpc DA neuron loss, suggesting
that a subset of nigral DA neurons may be morphologi-
cally intact, but functionally impaired.This concept is sup-
ported by the finding that 15% of melanized neurons in
the human SNpc no longer express tyrosine hydroxylase
(TH; the rate-limiting enzyme in DA synthesis), but
remain morphologically intact.
4
This concept of the suf-
fering, ie, metabolically compromised, neuron is impor-
tant in pathophysiological and therapeutic terms, since it
suggests that a subpopulation of nigral DA neurons are
amenable to restorative therapies.
After a general outline on the potential and limitations
of human postmortem studies in PD, I will explore major
questions regarding etiology, pathogenesis, and treatment
of PD with reference to human postmortem studies.
The role of human postmortem
studies in PD research
There has been considerable debate over the importance
of human postmortem studies in PD research. This con-
troversy is based on the many limitations of postmortem
research. Human postmortem studies in PD suffer from
T